Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma (NCT06043427)
A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
🩺 Plain-English Summary (8th-Grade Level)
This study is being done to answer the following question: Can the chance of gastroesophageal cancer growing or spreading be lowered by adding a drug called zanidatamab to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for gastroesophageal cancer
Who can join: Review the eligibility criteria below.
Location: Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
- BCCA - Vancouver — Vancouver, British Columbia
- CancerCare Manitoba — Winnipeg, Manitoba
- QEII Health Sciences Centre — Halifax, Nova Scotia
- Royal Victoria Regional Health Centre — Barrie, Ontario
- Juravinski Cancer Centre at Hamilton Health Sciences — Hamilton, Ontario
- Kingston Health Sciences Centre — Kingston, Ontario
- Waterloo Regional Health Network (WRHN) — Kitchener, Ontario
- London Health Sciences Centre Research Inc. — London, Ontario
- Lakeridge Health Oshawa — Oshawa, Ontario
- Ottawa Hospital Research Institute — Ottawa, Ontario
- Odette Cancer Centre — Toronto, Ontario
- St. Michael's Hospital — Toronto, Ontario
- University Health Network — Toronto, Ontario
- CHUM-Centre Hospitalier de l'Universite de Montreal — Montreal, Quebec
- Centre Integre Universitaire De Sante Et De Services — Montreal, Quebec
- Allan Blair Cancer Centre — Regina, Saskatchewan
- Saskatoon Cancer Centre — Saskatoon, Saskatchewan
📞 Contact the Study Coordinator
Phone: (613) 533-6430
Email: cocallaghan@ctg.queensu.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastroesophageal Adenocarcinoma
- Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) — Tampa, Florida
- RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial — Montreal,
- AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas — Los Angeles, California
- Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) — Orange, California
- A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma — Newark, Delaware
Explore by condition: All Gastroesophageal Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.